Evotec (EVT) investor relations material

Strategic vision and value creation

• Focus on pioneering drug discovery and operational excellence to drive above-market growth and quality earnings.

• Four levers for mid-term value: growth, operational excellence, monetization of technology/assets, and asset pipeline returns.

• Commitment to cost-out initiatives, productivity improvements, and a shift to an asset-lighter business model.

• Sale of Just-Evotec Biologics EU to Sandoz accelerates transition to a capital-efficient model and validates technology leadership.

• Enhanced commercial model targets higher-margin technology and IP revenue streams, expanding potential partnerships.

Market positioning and innovation

• Operates in attractive markets with global R&D spend of $260bn and strong outsourcing trends.

• Biologics CDMO market shows robust growth, with technology advantage shaping new segments.

• AI-enhanced drug discovery platforms and integrated services support high-value partnerships and asset pipeline expansion.

• Versatile commercial model offers tailored solutions, strategic partnerships, and risk/reward sharing.

• Next-generation CDMO model leverages innovation, IP licensing, and proprietary manufacturing platforms.

Financial performance and outlook

• FY 2025 saw strong JEB growth (39.8%) but softness in early discovery; group revenues slightly declined.

• H1 2026 marked by revenue decline due to timing effects and delayed partnership contributions.

• Solid liquidity maintained through portfolio monetization and financing, despite significant debt repayment.

• Updated 2026 guidance reflects delays in strategic partnership revenues, with improvements expected in 2027.

• Horizon transformation aims for €75m annual cost savings by 2027, with 20-30% realized in 2026.